Case Report: Adult EBV-associated hemophagocytic lymphohistiocytosis with presumed primary EBV infection: a report of three cases and diagnostic considerations.
4 affiliations
- 1Department of Hematology and Oncology, St. Marianna University School of Medicine, Kawasaki, Japan.
- 2The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
- 3Department of Hematology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan.
- 4Department of Hematology and Biophysical Systems Analysis, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan.
Abstract
Adult Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) is a clinically heterogeneous syndrome comprising biologically distinct disease entities. We report three adults with EBV-HLH and describe their diagnostic evaluation and clinical course. We presumed primary EBV infection from anti-VCA IgM positivity, anti-EBNA negativity, and a history of possible saliva-mediated exposure in all three patients. Personal and family histories did not suggest familial HLH (fHLH), and genetic analysis performed in one patient did not identify pathogenic variants of fHLH. No history nor clinical findings suggested an inborn error of immunity. Whole-body computed tomography did not show any mass lesions suggestive of malignancy, and bone marrow examination showed hemophagocytosis without abnormal lymphoid proliferation or other findings suggestive of lymphoma. No clonal immunoglobulin heavy-chain or T-cell receptor gene rearrangements were detected in any patient. EBV-infected cell phenotype was assessed by bone marrow pathology in two patients; EBER-positive CD3-positive T cells were identified in one, whereas the infected cell phenotype could not be determined in the other because of the limited number of cells. In the remaining patient, EBV-DNA quantification in sorted peripheral blood mononuclear cell fractions showed EBV infection of CD8-positive T cells. All patients responded to HLH-94/HLH-2004-based therapy including etoposide and were managed without hematopoietic stem cell transplantation (HSCT). During follow-up at our department for 345-1,067 days, no confirmed HLH recurrence was observed, although EBV-DNA remained detectable for more than one year in two patients. These cases suggest that EBV-DNA may remain detectable after clinical remission in adult HLH associated with presumed primary EBV infection. The indication for HSCT should be considered carefully, not on the basis of EBV-DNA positivity alone, but through longitudinal clinical assessment and reassessment for CAEBV, EBV-positive lymphoma, fHLH, and underlying immunodeficiency.
Related
- Hemophagocytic Lymphohistiocytosis in a Patient With Alcohol‐Associated Liver Disease: A Case Report Highlighting Diagnostic Challenges
- An Active Cytomegalovirus Infection and Epstein-Barr Virus Reactivation Complicated by Cytomegalovirus Meningitis and Virus-Associated Hemophagocytic Lymphohistiocytosis during Methotrexate and Upadacitinib Therapy in a Patient with Rheumatoid Arthritis
- Secondary hemophagocytic lymphohistiocytosis complicating culture-confirmed ceftriaxone-resistant Salmonella typhi infection: A rare case report.
- Brucella melitensis infection complicated by secondary hemophagocytic lymphohistiocytosis, meningitis, and multiorgan damage: a case report and literature review.
- Tuberculosis-Associated Hemophagocytic Lymphohistiocytosis with Bone Marrow Involvement: Case Report and Literature Review
BibTeX
@article{ishikawa2026case,
title = {{Case Report: Adult EBV-associated hemophagocytic lymphohistiocytosis with presumed primary EBV infection: a report of three cases and diagnostic considerations.}},
author = {Ayuri Ishikawa and Hiroshi Yasui and Sanshiro Uchida and Kumi Oshima and Fumiaki Sano and Ayako Arai},
journal = {Frontiers in medicine},
year = {2026},
month = oct,
doi = {10.3389/fmed.2026.1950374},
url = {https://europepmc.org/article/MED/42908677},
note = {CC BY},
}
RIS
TY - JOUR
TI - Case Report: Adult EBV-associated hemophagocytic lymphohistiocytosis with presumed primary EBV infection: a report of three cases and diagnostic considerations.
AU - Ayuri Ishikawa
AU - Hiroshi Yasui
AU - Sanshiro Uchida
AU - Kumi Oshima
AU - Fumiaki Sano
AU - Ayako Arai
PY - 2026
DA - 2026/10/07
JO - Frontiers in medicine
DO - 10.3389/fmed.2026.1950374
UR - https://europepmc.org/article/MED/42908677
AB - Adult Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) is a clinically heterogeneous syndrome comprising biologically distinct disease entities. We report three adults with EBV-HLH and describe their diagnostic evaluation and clinical course. We presumed primary EBV infection from anti-VCA IgM positivity, anti-EBNA negativity, and a history of possible saliva-mediated exposure in all three patients. Personal and family histories did not suggest familial HLH (fHLH), and genetic analysis performed in one patient did not identify pathogenic variants of fHLH. No history nor clinical findings suggested an inborn error of immunity. Whole-body computed tomography did not show any mass lesions suggestive of malignancy, and bone marrow examination showed hemophagocytosis without abnormal lymphoid proliferation or other findings suggestive of lymphoma. No clonal immunoglobulin heavy-chain or T-cell receptor gene rearrangements were detected in any patient. EBV-infected cell phenotype was assessed by bone marrow pathology in two patients; EBER-positive CD3-positive T cells were identified in one, whereas the infected cell phenotype could not be determined in the other because of the limited number of cells. In the remaining patient, EBV-DNA quantification in sorted peripheral blood mononuclear cell fractions showed EBV infection of CD8-positive T cells. All patients responded to HLH-94/HLH-2004-based therapy including etoposide and were managed without hematopoietic stem cell transplantation (HSCT). During follow-up at our department for 345-1,067 days, no confirmed HLH recurrence was observed, although EBV-DNA remained detectable for more than one year in two patients. These cases suggest that EBV-DNA may remain detectable after clinical remission in adult HLH associated with presumed primary EBV infection. The indication for HSCT should be considered carefully, not on the basis of EBV-DNA positivity alone, but through longitudinal clinical assessment and reassessment for CAEBV, EBV-positive lymphoma, fHLH, and underlying immunodeficiency.
SN - 2296-858X
ER -